ArticleScientific reports2026
Binding properties of marine sulfated glycans to coagulation (co)-factors using surface plasmon resonance spectroscopy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Marine sulfated glycans (MSGs) are a rich source of novel structures with unique biological activities, particularly in anticoagulation and antithrombosis. MSGs, such as fucosylated chondroitin sulfates (FucCSs) and sulfated fucans (SFs), exhibit anticoagulant properties influenced by their molecular weight, monosaccharide composition, glycosidic linkages, sulfation patterns, and fucosylation levels. Unlike traditional anticoagulants like unfractionated heparin (UFH) and low molecular weight heparin (LMWH), MSGs offer alternative mechanisms, potentially providing a safer therapeutic profile. Despite the recognized anticoagulant potential of MSGs, their binding mechanisms with coagulation factors and the role of metal ions to enhance binding have not been fully explored. This study investigates the binding properties of MSGs from various echinoderm species with key coagulation factors (thrombin, and factor Xa) and serpins (antithrombin, and heparin cofactor II) using surface plasmon resonance. We assessed the inhibitory effects of defined FucCSs and SFs on these interactions, using UFH and LMWH as controls. Our results show that MSGs exhibit antithrombin-independent anticoagulant activity and interact with heparin cofactor II and factor Xa, with metal ions playing a crucial role in some of these bindings. This comprehensive analysis highlights MSGs as promising anticoagulants with potential advantages in safety and efficacy compared to traditional agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.